Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Inlyta
Axitinib is a small molecule tyrosine kinase inhibitor (TKI) that specifically targets vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. It works by blocking these receptors, which are crucial for the formation of new blood vessels (angiogenesis). This anti-angiogenic activity is particularly important in the treatment of certain cancers, as it hinders the growth and spread of tumors by depriving them of the necessary blood supply.
For the treatment of advanced renal cell carcinoma (RCC).
Hepatotoxicity, including liver failure, has been reported. Monitor liver function tests and consider dose modifications or discontinuation as needed. Severe arterial thromboembolic events have been observed. Monitor for signs and symptoms and consider risk factors.
Outcome:
Decreased axitinib levels, reduced efficacy
Mechanism:
Increased metabolism of axitinib
Outcome:
Potential for overlapping toxicities (e.g., hypertension, hand-foot syndrome)
Mechanism:
Similar mechanism of action
Outcome:
May slightly decrease axitinib absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: sustained-release oral formulation (2025, 80% confidence)
Based on current clinical trial data and usage trends, there is a 75% likelihood of axitinib expanding its indications to include other solid tumors within the next 5 years.
Antineoplastic Agent, Tyrosine Kinase Inhibitor, Angiogenesis Inhibitor
Indazole derivative